Weldhagen Gerhard F, Prinsloo Andrea
Department of Medical Microbiology, Faculty of Health Sciences, University of Pretoria, Pretoria 0001, South Africa.
Int J Antimicrob Agents. 2004 Jul;24(1):35-8. doi: 10.1016/j.ijantimicag.2003.12.012.
Screening for and detection of the novel extended spectrum Beta-lactamase (ESBL), GES-2 produced by Pseudomonas aeruginosa remains a problem in the clinical microbiology laboratory. This study aimed to compare the normally used ESBL screening agent ceftazidime, with molecular detection, to demonstrate the presence of GES-2 ESBL production in clinical isolates of P. aeruginosa. Ceftazidime was found unreliable as an ESBL screening agent, with a specificity of 34.4%, when National Committee for Clinical Laboratory Standards resistance criteria for P. aeruginosa were employed. An improved PCR detection method was devised, that amplified a 371 bp segment of bla(GES-2). This should lead to more cost-effective DNA sequencing and sequence interpretation in the laboratory.
对铜绿假单胞菌产生的新型超广谱β-内酰胺酶（ESBL）GES-2进行筛查和检测，在临床微生物实验室中仍然是一个难题。本研究旨在将常用的ESBL筛查试剂头孢他啶与分子检测方法进行比较，以证明铜绿假单胞菌临床分离株中GES-2 ESBL的产生情况。当采用美国国家临床实验室标准委员会（National Committee for Clinical Laboratory Standards）针对铜绿假单胞菌的耐药标准时，发现头孢他啶作为ESBL筛查试剂并不可靠，其特异性为34.4%。设计了一种改进的PCR检测方法，该方法可扩增bla(GES-2)的一个371 bp片段。这将使实验室中的DNA测序和序列解读更具成本效益。
